source
- Biogen shifts M&A strategy as Apellis acquisition pushes revenue above analyst expectationsBiogen officially began reporting revenue from the $5.6 billion acquisition of Apellis in the second quarter, shaking up analysts’ consensus estimates and leading to a beat.
- Fugitive Discovered Working Under Alias in Biotech Industry Amid Legal Battles Involving AstraZeneca and LillyA Rhode Island fugitive who had been on the most-wanted list was recently uncovered as having worked under a false identity in the biotech sector. The revelation raised questions about how the ind…